LOGIN  |  REGISTER
C4 Therapeutics

Rhythm Pharmaceuticals (NASDAQ: RYTM) Stock Quote

Last Trade: US$40.00 0.99 2.54
Volume: 413,648
5-Day Change: -0.22%
YTD Change: -12.99%
Market Cap: US$2.410B

Latest News From Rhythm Pharmaceuticals

BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on April 11, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 31,220 shares of its common... Read More
BOSTON, April 01, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it has signed an investment agreement with current shareholders, led by Perceptive Advisors LLC and its Discovery Fund and a life-sciences focused institutional... Read More
Three-part study to evaluate safety, tolerability and pharmacokinetics now underway RM-718 showed potential to reduce body weight and hyperphagia, no hyperpigmentation observed in preclinical studies BOSTON, March 25, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare... Read More
BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on March 6, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,780 shares of its common stock... Read More
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Company will participate in two upcoming investor conferences. David Meeker, M.D., Chair, President and Chief Executive Officer, will participate in a fireside... Read More
Supplemental cohort of 12 Japanese patients to be added to global Phase 3 hypothalamic obesity trial, with dosing expected to begin in third quarter of 2024 Significant unmet need with 5,000 to 8,000 patients with hypothalamic obesity estimated to be living in Japan BOSTON, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on... Read More
Fourth quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $24.2 million Enrollment completed in 120-patient, pivotal cohort of Phase 3 setmelanotide trial in hypothalamic obesity; top-line data on track for 1H2025 Announced Phase 3 development plans for setmelanotide in hypothalamic obesity in Japan Spain and Italy authorities approve reimbursement for IMCIVREE to treat patients with Bardet-Biedl... Read More
BOSTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on February 2, 2024, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 20,295 shares of its common... Read More
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that the Italian Medicine Agency (AIFA) approved reimbursement ( Gazzetta Ufficiale ) for IMCIVREE ® (setmelanotide) for the treatment of obesity and control of... Read More
BOSTON, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, February 22, 2024 to report its fourth quarter and full year 2023 financial results... Read More
BOSTON, Jan. 12, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced that on January 9, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity grants covering an aggregate of 13,020 shares of its common... Read More
LB54640 has shown targeted effect on MC4 receptor without hyperpigmentation Rhythm to advance LB54640 in two Phase 2 clinical trials BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced it has entered into a global... Read More
Phase 3 hypothalamic obesity top-line data expected in 1H2025 Positive reimbursement decision achieved for IMCIVREE ® (setmelanotide) to treat patients with Bardet-Biedl syndrome and POMC/LEPR deficiencies in Spain IND application for RM-718 accepted by the FDA BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the... Read More
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc . (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on December 7, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement... Read More
More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases Approximately 150 healthcare professionals from 20 countries expected to attend BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc . (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living... Read More
Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR deficiency or BBS RM-718 showed potential to reduce body weight and hyperphagia with no off-target cardiovascular effects and no hyperpigmentation observed... Read More
BOSTON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on November 8, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement... Read More
Third quarter 2023 net revenue from global sales of IMCIVREE ® (setmelanotide) of $22.5 million More than 100 international patients on reimbursed IMCIVREE therapy Phase 3 hypothalamic obesity trial on track to be fully enrolled by the end of 2023 25.5% mean BMI reduction achieved at one year of setmelanotide therapy in patients with hypothalamic obesity (n=12) who transitioned to long term extension from Ph 2 trial; three... Read More
CADTH recommends reimbursement for weight management in adult and pediatric patients six years of age and older with obesity due to Bardet-Biedl syndrome (BBS)​ Recommendation based on demonstrated clinical benefit in Phase 3 trial BOSTON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their... Read More
BOSTON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, November 7, 2023 to report... Read More
Patients with hypothalamic obesity (n=12) achieved mean BMI reduction of 25.5% at one year on setmelanotide treatment Three of 11 pediatric patients with hypothalamic obesity achieved normal weight at one year based on NIH, WHO weight classifications Additional long-term study data show clinically relevant weight reductions in patients with Bardet-Biedl syndrome and POMC or LEPR deficiency obesity Conference call scheduled... Read More
BOSTON, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on October 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement... Read More
BOSTON, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that six abstracts have been accepted for presentation – three oral presentations and three posters - at The... Read More
BOSTON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced four oral presentations at the 61 st Annual European Society for Paediatric Endocrinology (ESPE) Meeting... Read More
BOSTON, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that the European Medicines Agency (EMA) has issued a positive opinion on the Company’s orphan drug... Read More
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on Sept. 5, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
BOSTON, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced an update to its September conference calendar. The Company has cancelled its participation in the H.C.... Read More
BOSTON, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for... Read More
BOSTON, Aug. 28, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that Company management will present at three investor conferences in September: 2023 Wells Fargo Healthcare... Read More
Reimbursed early access program allows for patients with hypothalamic obesity in France to receive setmelanotide treatment Early access designation for hypothalamic obesity comes in addition to Bardet-Biedl syndrome BOSTON, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with... Read More
BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on August 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
Second quarter 2023 net revenue of $19.2 million from global sales of IMCIVREE ® (setmelanotide) Strong U.S. commercial progress continues with more than 125 new prescriptions for Bardet-Biedl syndrome (BBS) in 2Q 2023, more than 425 since FDA approval Achieved commercial sales milestone and now eligible to receive third investment tranche of $25 million from Healthcare Royalty Partners Announced plans to submit an... Read More
BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced two new publications detailing the burden of hyperphagia and obesity for adult caregivers, families and... Read More
BOSTON, July 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 1, 2023 to report... Read More
BOSTON, July 13, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on July 10, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
Mean BMI reduction of 21.0% from baseline observed in 13 patients at six months, showing progression from 16.8% mean BMI reduction at 16 weeks Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity ongoing; completion of enrollment expected 1Q 2024 BOSTON, June 17, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the... Read More
BOSTON, June 07, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat... Read More
BOSTON, June 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on June 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
BOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced a collaboration with Genpharm Services FZ LLC (Genpharm) to commercialize IMCIVREE ® (setmelanotide) in Gulf... Read More
First and only approved therapy in Canada that targets genetic impairment in the MC4R pathway - a root cause of early-onset, severe obesity in these patients Approval granted following a Priority Review by Health Canada BOSTON, May 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company, today announced that Health Canada has approved IMCIVREE ® (setmelanotide... Read More
BOSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on May 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
Strong U.S. commercial progress continues for IMCIVREE ® (setmelanotide) with more than 300 new prescriptions for Bardet-Biedl syndrome (BBS) received since FDA approval Launched IMCIVREE for BBS in Germany with federal reimbursement First patients dosed in pivotal Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity; completion of enrollment expected 1Q 2024 Executing on six clinical trials with three... Read More
BOSTON, April 24, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced the commercial launch of IMCIVREE ® (setmelanotide) in Germany for the treatment of obesity and control of... Read More
BOSTON, April 18, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, May 2, 2023 to report its... Read More
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that David Meeker, M.D., Chair, Chief Executive Officer and President, will participate in a fireside chat... Read More
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on April 4, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
Interview-based research published in Advances in Therapy demonstrates setmelanotide improved hyperphagia and reduced body weight and obsessive focus on food Company also announces publication of health state utilities study in hyperphagia BOSTON, March 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their... Read More
BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on March 1, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
IMCIVREE ® U.S. launch for Bardet-Biedl syndrome (BBS) reflects strong demand with more than 200 new prescriptions received since FDA approval IMCIVREE now available in eight ex-U.S. markets; first commercial sales for BBS expected in Germany in 2Q 2023 Pivotal Phase 3 trial evaluating setmelanotide in acquired hypothalamic obesity initiated Acquired Xinvento B.V., a rare disease company in preclinical development for... Read More
Rare disease company in preclinical development for congenital hyperinsulinism Acquisition is strong strategic fit with Rhythm’s rare endocrinology focus and provides meaningful new development opportunity Expect to initiate clinical development in 2024 BOSTON and AMSTERDAM, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on... Read More
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Wednesday, March 1, 2023 to report... Read More
BOSTON, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on February 2, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement... Read More
Patients reported clinically meaningful improvements across multiple health-related quality of life measures following 52 weeks of treatment with setmelanotide Analysis published in Orphanet Journal of Rare Diseases BOSTON, Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with... Read More
BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) pathway diseases, today announced that on January 3, 2023, the Compensation Committee of Rhythm’s board of directors granted inducement equity... Read More
Cue Biopharma

COPYRIGHT ©2023 HEALTH STOCKS HUB